Explore the words cloud of the Gut_Fights_PD project. It provides you a very rough idea of what is the project "Gut_Fights_PD" about.
The following table provides information about the project.
Coordinator |
THE UNIVERSITY OF EDINBURGH
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 183˙454 € |
EC max contribution | 183˙454 € (100%) |
Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
Code Call | H2020-MSCA-IF-2017 |
Funding Scheme | MSCA-IF-EF-ST |
Starting year | 2019 |
Duration (year-month-day) | from 2019-09-01 to 2021-08-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | THE UNIVERSITY OF EDINBURGH | UK (EDINBURGH) | coordinator | 183˙454.00 |
The recent discovery that the composition of the gut microbiota can influence the symptoms of neurodegenerative diseases is a paradigm shift in how we view these conditions. In Parkinson’s disease (PD), patients frequently experience gastrointestinal symptoms years before the development of motor deficits and recent studies reveal clear alterations in the gut microbiota composition at advanced stages, which correlate with severity of their symptoms. Therefore, understanding the molecular mechanisms by which gut bacteria interact with the host to affect the nervous system may uncover novel prognostic and therapeutic strategies for neurological diseases. To address this gap of knowledge, we propose a single bacteria-worm model as a genetically tractable system to mechanistically investigate the connection between bacterial metabolites produced in the gut and neurodegeneration. Preliminary data from the lab on a protein aggregation model of PD in C. elegans, show a strong protective effect of a human probiotic bacterial species on α-synuclein aggregation, a well-established factor in Parkinson’s disease. The aim of this project is to understand the mechanisms through which the probiotic bacteria act to protect from α-syn aggregation and the nature of the response induced in the nematode. We are proposing a bidirectional strategy, manipulating genetically both players in this interaction, the bacteria and the nematode. Using a candidate molecular approach based on available data and an unbiased high-throughput analysis, we expect to elucidate new metabolic pathways employed by the bacteria to modulate protein aggregation as well as the molecular mechanisms that elicit this response in the nematode. By directly testing on various C. elegans models of PD the pharmacological effect of the discovered beneficial metabolites, we will identify specific neuroprotective compounds with future therapeutic potential.
year | authors and title | journal | last update |
---|---|---|---|
2020 |
MarÃa Eugenia Goya, Feng Xue, Cristina Sampedro-Torres-Quevedo, Sofia Arnaouteli, Lourdes Riquelme-Dominguez, Andrés Romanowski, Jack Brydon, Kathryn L. Ball, Nicola R. Stanley-Wall, Maria Doitsidou Probiotic Bacillus subtilis Protects against α-Synuclein Aggregation in C. elegans published pages: 367-380.e7, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.12.078 |
Cell Reports 30/2 | 2020-02-06 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GUT_FIGHTS_PD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GUT_FIGHTS_PD" are provided by the European Opendata Portal: CORDIS opendata.
Neural mechanisms of crossmodal activity in blind and sighted individuals
Read MoreQuantitative insight into chromatin nanoscale structure: sub-nuclear organisation of oncoprotein DEK
Read MoreMonitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells
Read More